key: cord-1031656-zdepg05e
authors: Hammoumi, A.; Hmarrass, H.; Qesmi, R.
title: Impact of booster COVID-19 vaccine for Moroccan adults: A discrete age-structured model approach
date: 2021-03-17
journal: nan
DOI: 10.1101/2021.03.14.21253555
sha: 70757cda2e221a6fb679201f6e04d88847cd5b65
doc_id: 1031656
cord_uid: zdepg05e

Public health control strategies, such as lockdown, seem to be effective in reducing the spread of the pandemic, but are ineffective as a whole since lockdown is responsible of global economic crisis and badly lived by the majority of children and adults who have developed mental health disorders and familial problems as well. Thus, the development of a vaccine against COVID-19 is needed to control this disease. We have developed a discrete age-structured model and followed the Moroccan vaccination program to assess the impact of booster vaccination targeting Moroccan adults against COVID-19. Using the derived model, we estimated some relevant model parameters related to COVID-19 using collected cumulative mortality and reported Moroccan data. A control reproduction number R_{c}, which determines the necessary level of vaccine uptake that lead to COVID-19 eradication is determined. Furthermore, a herd immunity threshold above which the population can be protected from COVID-19 infection is derived. Analyzing the model, sufficient and necessary conditions for the eradication of the disease are obtained as well. Next, we perform numerical simulations to study the impact of several uptake levels of the potential vaccine on the persistence and the extinction of COVID-19 pandemic. Our results show that the COVID-19 is expected to last past 2021 in the absence of a vaccination program. Moreover, a vaccination of the adult population at rate 0.6% per day needs at least 67% of vaccine efficacy and 90% of immunogenicity rate to eradicate the disease. Using Sinopharm vaccine, the herd immunity can be achieved when about half of Moroccan adult population is immunized against the COVID-19. However, using Oxford-Astrazeneca vaccine, less than 60% of adult population must be immunized against the disease to achieve the herd immunity. Finally, if vaccine efficacy is about 80% and the immunogenicity is about 50% then vaccinating adults at rate of 0.6% per day could protect roughly 22% of children from COVID-19 infection.

The newly emerging coronavirus diseases become constant threats to global public health [50] . There are seven coronaviruses (CoVs) known to infect humans so far [63] . Among them, three have caused more severe respiratory illness and fatalities including SARS-CoV, to be among the countries to conduct a mass emergency vaccination campaign against the COVID-19. Since the end of December 2020, the Moroccan Kingdom intends to launch an emergency vaccination program for the adult population upon immediate receipt of the first pre-ordered doses of vaccines from the Sinopharm or Astrazeneca companies. It will cover 80% of the population aged over 18 years old. The program will be conducted over a period of 12 weeks in which people will receive two doses of vaccine separated by 21 days in average.

Mathematical modeling has proven to be a powerful tool to predict the dynamics of the epidemic and to help decision makers to evaluate the effectiveness of public health control interventions (See [31, 38, 53, 19] and references therein). Furthermore, mathematical models can be used to assess whether a vaccination strategy will be effective in eradicating or controlling a disease. Using a mathematical model of COVID-19 vaccine portfolio in [34] , Their results suggests that, by the end of April 2021, there is a 50% of chance that a safe and efficient vaccine can be approved by the end of 2021. Furthermore, it could take more than a year to produce sufficient vaccines to cover 50 million medical staff in the entire world. In [26] , Peter Jentsch et al. developed an age-structured SEAIR model of with vaccination in Ontario to check whether it is better to vaccinate the most vulnerable individuals or those who spread the virus further to others. They found that using vaccines to break the spread could minimize mortality impressively than using the vaccines selecting elderly people. Tom Britton et al. in [7] developed an age-structured mathematical model according to social activity level. They estimated that if the basic reproduction number reaches 2.5, then the disease-induced herd immunity level could reach 43%, which is lower than the classical herd immunity level. Mukandavire et al. used a mathematical model fitted to COVID-19 daily new cases in South Africa to estimate the critical vaccination coverage that control the disease for different vaccine efficacy levels. They estimated that a vaccine with 70% efficacy can eradicate COVID-19 disease in south Africa [36] . In [17] , Enahoro In this work, we develop a discrete age-structured model with a booster vaccination, focusing on an established path of COVID-19 transmission from children to adults and vice versa. In other words, we present a model, splitting the population into two different cohorts, to focus our investigation on a vaccination program targeting adults aged over 18 years. Since the developed COVID-19 vaccine may not always hold when carried out to the patient and doesn't always protect against infection [21, 27] , our model will include varying efficacies and immunogenecities of the vaccine against COVID-19. The model is a useful tool, which will be used to assess the vaccination rate, efficacy and the immunogenicity of vaccine needed to eradicate the COVID-19 according to the intended strategy followed by the Moroccan Government.

The data of reported symptomatic infectious and death cases is collected each day at 11 pm from the official Coronavirus Portal of Morocco [48] . Data information, as shown in 

The population considered in this section is stratified into two age categories and eight disease status. Individuals are classified as unvaccinated susceptible children (T u ), unvaccinated susceptible adults (S u ), vaccinated susceptible adults (S v ), asymptomatic infectious adults (A), asymptomatic infectious children (B), unreported symptomatic infectious (I u ), hospitalized symptomatic infectious (H), recovered individuals (R) and COVID-deceased individuals (D). We assume that infected children do not show symptoms and can still transmit the disease. COVID-19 disease dynamics can be described as follows: Susceptible children are born at rate π T and move to the susceptible adult class at rate α. Unvaccinated susceptible individuals that are vaccinated at rate p and acquire immunity from the vaccine at rate move to the vaccinated class (S v ) . It is assumed that vaccination does 4 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint not necessarily induce lifelong immunity. Thus, vaccinated susceptible individuals are also assumed to acquire COVID-19 infection with a protective efficacy ψ, following effective contact with asymptomatic or unreported infected individuals. Furthermore, it is assumed that vaccinated class (S v ) receives a booster dose as a second administration of the vaccine, at a rate φ, to maintain successful immunization. Unvaccinated susceptible adults (S u ) (resp. vaccinated susceptible adults (S v ), susceptible children (T )) are infected through contact with infectious adults (A + I u ) at a transmission rate β aa (resp. (1 − ψ) β aa , β ca ) or through contact with infectious children (B) at a transmission rate β ac (resp. (1 − ψ) β ac , β cc ). Once infected, children and adults move, respectively, to the asymptomatic infectious class (B) and the asymptomatic infectious class (A). After an average period 1/δ days the asymptomatic infectious individuals (A) become symptomatic and proceed either to the unreported symptomatic infectious (I u ), at rate δ 1 , or to the hospitalized individual (H) at rate δ 2 with δ = δ 1 +δ 2 . Once becoming symptomatic, individuals of class I u and H either remain asymptomatic for 1/µ days on average before they are recovered or remain asymptomatic for 1/d days on average before they are dead due to infection. Asymptomatic children can either be recovered without being hospitalized at rate δ or detected and hospitalized at rate σ. All individuals are naturally dead at rate d N . The model will be given by the following

(2.1)

To estimate the model parameters we will use the data between March 2nd and March 20th,2020 during which there were no control measure. We will assume that S v = 0, p S = 0 and = 0. Note that the first infected child under 18 years was reported 22 days since the beginning of the epidemic. Furthermore, the maximum asymptomatic duration is assumed to 5 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted March 17, 2021. ; https://doi.org/10.1101/2021.03.14.21253555 doi: medRxiv preprint be around 6 days. Consequently, it is meaningful to assume that there were no asymptomatic infected children (i.e. B(0) = 0) under 18 years old at time t = 0.

The cumulative reported infectious population is given, for t ≥ 0, by F (t) = δ 2 t 0 A(s)ds+ 1. It is obvious that cumulative reported infectious population increases slowly and then accelerates rapidly with time. Hence, we will use exponential regression with 95% of confidence level to find an exponential function that best fits the data, from March 2nd to June 10th. Using SPSS software (Statistical Package for the Social Sciences) we found that the exponential model, given by be at where a = 0.263 with confidence interval CI (0.229 − 0.297) and b = 0.507 with CI (0.3444 − 0.7475) fits well the data with a correlation coefficient given by R = 0.97. It follows from F (t) = δ 2 t 0 A(s)ds + 1 = be at that [20] 6 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted March 17, 2021. ;  Since the initial susceptible population is not dramatically affected in the early phase of the epidemic, we will assume that S u (t) ≈ S u (0). Let S 0 := S u (0), A 0 := A(0) and I 0 := I u (0). From the fifth equation of system (2.1) and using (2.2) we obtain

where

Now, using formulas (2.3) and the sixth equation of system (2.1), we obtain after simplifi-

It follows that

Furthermore, S v (0) = 0, T u (0) = 12437000 and S u (0) = 23428191. We calculate the leaving rate of children under 18 years old to adults as 1/α = 18 × 365 days, thus, α = 1, 52 × 10 −4 .

Since the Moroccan authorities decided to give the second dose of the vaccine after 21 days following the first dose then we assume that φ = 1/21. As mentioned in Section 1, we assume that β ac = β aa and β ca = β cc . To estimate the transmission rates, β aa , β cc and d, we use the nonlinear least squares solver "lsqcurvefit" in MATLAB R2019b software. The values of the estimated parameters are summarized in Table 1 .

Since the three last components H,R and D do not appear in the six first equations of model (2.1) then we will focus our local stability study on the following system. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted March 17, 2021. ;  It is obvious that the model (3.1) has a unique disease free equilibrium (DFE) which is given

The control reproduction number, R c , is an important value, used to determine whether a control policy, such as lockdown, lifting, behavioral practices, vaccination, etc, will be efficient to decrease the number of secondary infections to be less than one. In the absence of any control, this number is considered as the basic reproduction number, R 0 , which is the average number of secondary infections produced when one infectious individual is introduced into a host susceptible population. This quantity determines whether a given disease may spread, or die out in a population. Applying the next generation matrix method formulated in [51] , R c can be given by

The calculation of R c can be found in Appendix A.

The local behavior of the DFE of system (3.1) is given by the following theorem.

Theorem 1. The disease-free equilibrium is locally asymptotically stable for R c < 1 and unstable for R c > 1.

The proof of Theorem 1 can be found in Appendix B. The next lemma will be useful to prove the global stability of the DFE.

is positively invariant and attracting with respect to system ((3.1)).

The proof of Lemma 2 can be found in Appendix C.

Put

.

. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted March 17, 2021. ;  Theorem 3. Assume that Θ < 1 and R c ≤ 1 , then the disease free equilibrium E of system ((3.1)) is globally asymptotically stable in the region Ω, i.e,

The proof of Theorem 3 can be found in Appendix D.

Remark 4. Using parameter values in Table 3 It follows that, in order to assure the global asymptotic stability, it suffices to assume that R c ≤ 1.

Herd immunity is defined as a level of population immunity at which the amount of virus able to spread in the entire population becomes very low so that the spread of the disease will be over. However, if the immunity level does not reach the herd immunity level, then a second wave of disease spread may appear. Thus, it is an interesting to look when herd immunity can be reached. Although natural herd immunity is considered as a way to reach herd immunity through natural recovery from COVID-19 infection, vaccination is considered as the best way to protect susceptible individuals and their community. Indeed, once plenty individuals are vaccinated and get immune from the disease, viruses cannot pass between individuals in the population and the whole community is less probably to contract the disease.

Note that the quantity ϕ, given in (A.1), can be written as

Thus, R c will be given by

.

where N is the total population size. Let h v = Sv N and h T = Tu N , respectively, be the the proportions of susceptible individuals that have been vaccinated and susceptible children at the disease-free equilibrium. Set

. CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted March 17, 2021. ;  where

Note that, following Theorem 3 and Remark 4, the disease free equilibrium E of system

h v > h c v and, thus, for the herd immunity to be achieved, a proportion h c v , which is known as the herd immunity threshold, of the entire population should be vaccinated. Furthermore, if the vaccination is not successful at all (ψ = 0) then no matter the proportion of vaccinated adults, the eradication of the COVID-19 disease is implausible.

The vaccination is among the most effective methods of preventing disease, disability, and death. A vaccine is defined as a suspension of live attenuated or inactivated pathogens, or fractions thereof, which is administered to induce immunity and prevent infectious disease or its sequelae [46] . Throughout 2020, a global effort have been undertaken to produce safe and effective vaccines against the newly emerged coronavirus, SARS-CoV-2. Actually, several of them received approval to initiate the national and multi-country mass vaccination campaigns. Morocco also will launch an emergency vaccination program for the adult population using vaccines produced by pharmaceutical firm Sinopharm and Astrazeneca.

Over a period of 3 months, susceptible adult people who volunteer for the vaccination will receive two injections of vaccine spaced by 21 days apart [49] . Generally, the first dose induces a primary immune response by exposing the body for the first time to antigens. This immune response is often slow, limited and do not lead to protective immunity [45] .

Therefore, a subsequent dose, also called a booster shot, is required to induce a secondary immune response in order to maintain an immunological memory which provides a long-time immunity. Indeed, the long-lived antibodies and memory cells have the ability to respond faster and more efficiently to the re-exposure to the same antigens [1] . Unfortunately, it is still too early to assess the duration of immunity provided by all anti-COVID-19 vaccines [3, 9] . Moreover, our understanding to the magnitude and duration of the immune response to natural infection with SARS-CoV-2 remains limited to date [12] . But it is well known that, for the common coronaviruses, the protective immunity is short-lasting and the reinfection often occurs 12 months after infection [8, 16] . For the SARS-CoV-2, several studies have shown that the immunity wanes over time and can be maintained only for few months after infection [54, 25, 44, 14] . Furthermore, the report of many cases of secondary infections with the COVID-19 in the same year also provides evidence that the acquired immunity is short-lived [16] . In case the protective immunity, conferred by the infection, is transient like for the coronavirus diseases, it will be necessary to plan periodic vaccination campaigns in coming years to prevent future outbreaks [40, 12] .

In this study, we used a discrete age-structured mathematical model to assess the SARS- is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint They also found that, in the absence of NPI, the vaccines with at least 70% efficacy are able to contain COVID-19 outbreak but higher vaccination coverage is needed. In the case of 11 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted March 17, 2021. ; https://doi.org/10.1101/2021.03.14.21253555 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint COVID-19, the herd immunity threshold is still unknown and will probably vary depending on the community and the vaccination strategy adopted by the country in question among others [62] . However, several studies using mathematical modeling were able to estimate this threshold [24, 4, 36] . For example, by assuming a vaccine with 80% of efficacy, Iboi and collaborators [24] found that at least 82% of susceptible population in US must be immunized against the SARS-CoV-2 to achieve the herd immunity threshold. Moreover, they also found that this percentage could drop to 72% (resp. 46%) with a regular wearing of masks by the half of the population (resp. the entire population). In our case, the herd immunity is achieved when about half of Moroccan adult population is immunized against the COVID-19 with a vaccine efficacy rate of 79% like the one by Sinopharm vaccine (See These proportions should probably be higher than estimated since our model also takes into account the combined effects of the NPIs and vaccine.

Finally, note that COVID-19 vaccines obviously provide direct protection to adults but can also produce indirect protection and block the course of infection to children. The   Fig. 4 .5 shows that, if vaccine efficacy is about 80% and the immunogenicity is about 50%, then protected susceptible children increases as vaccine uptake increases in the total adult population. In particular, 0.6% of vaccinated adults could save about 22% of children from infection.

While waiting for the first doses of vaccines since the end of December 2020, Morocco is preparing for the vaccination campaign of the adult population to eradicate the COVID-19

epidemic. Our findings show that, with a vaccination rate of 0.6% per day, the vaccine must both have an efficacy rate of at least 67% and must provide a high degree of immunity to people vaccinated. In addition, it is also necessary to continue to take protective measures during the vaccination period to achieve the herd immunity threshold more quickly. Our results found that the herd immunity can be obtained by immunizing less than 60% of the adult population against the COVID-19 with a vaccine with 70% or more of efficacy. Finally, this vaccination program can also protect 22% of susceptible children from infection.

However, in order not to devalue the efficacy of the vaccine used and before starting vaccination campaign, the Moroccan government must ensure the availability of all doses of vaccine needed to cover the entire target population, encourage the concerned people to be vaccinated, and carry out all vaccinations in the shortest time in accordance with the human, logistical and financial resources of country.

The authors thank the anonymous referees, whose careful reading, insights, valuable comments, and suggestions significantly enabled us to improve the quality of the paper.

Following the notation in [51] , the associated next generation matrices, F and V , for the new infection terms and the transition terms, are given, respectively, by

. CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted March 17, 2021. ; https://doi.org/10.1101/2021.03.14.21253555 doi: medRxiv preprint

.

. Then, the inverse of V is given by

Thus, the next generation matrix for system ((3.1)) will be given by

,

,

.

Therefore the associated characteristic equation is given by

and

. CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted March 17, 2021. ;  https://doi.org/10.1101/2021.03.14.21253555 doi: medRxiv preprint Therefore, by definition of R c , we obtain

Consequently, the control reproduction number is given by formula (3.2) .

The local stability of E is governed by the eigenvalues of the Jacobian matrix, of system ((3.1)), 

, a 3,1 = α,

,

,

,

, a 4,3 = p S ε,

,

,

Therefore the associated characteristic equation is is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted March 17, 2021. ;  where

,

and

.

are roots of the characteristic equation (B.1) and, consequently, a necessary and sufficient condition for the other roots ta have negative real parts is given by the following lineard-chipart [32] criteria

On can see that

Moreover, if R c < 1, then

It follows that

17 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint Thus, if R c < 1 then α 1 and α 3 are positive. Now let's prove that α 1 α 2 − α 3 > 0. After few simplification we can get

and, consequently,

Furthermore, from ((B.2)), we have

Finally, we have α 1 α 2 − α 3 > 0. Hence, E is locally asymptotically stable for R c < 1.

Assume now that R c > 1. Since

then P (0) < 0. Moreover, when λ ∈ R then lim λ→+∞ P (λ) = +∞ , Then, there exists λ 0 > 0 such that P (λ 0 ) = 0 and the disease-free equilibrium becomes unstable. This completes the proof.

For the invariance property it suffices to show that the vector field, on the boundary, does not point to the exterior. On one hand, on the boundary of Ω, we have

Then

and, consequently, dM dt ≤ 0. Therefore, solutions starting from Ω, will remain there for t ≥ 0. On the other hand, we have lim

Hence, Ω is attracting, that is, all solutions of ((3.1)) eventually enters Ω. This completes the proof.

To prove the above result, we use the following Lyapunov function

18 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted March 17, 2021. ; https://doi.org/10.1101/2021.03.14.21253555 doi: medRxiv preprint

The orbital derivative of W is given by

Since

Thus,

Notice that β cc π T d N 1 + (d N (σ + δ + d N + α) − β cc π T ) (d N α + β cc π T (2 − ψ)) (2 − ψ) = σ+δ+d N +α− α (d N (σ + δ + d N + α) − β cc π T ) (d N α + β cc π T (2 − ψ)) and π T d N 1 + d N (σ + δ + d N + α) − β cc π T d N α + β cc π T (2 − ψ) (2 − ψ) = (σ + δ + d N + α) (2 − ψ) + α (d N α + β cc π T (2 − ψ)) π T .

. CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted March 17, 2021. ; https://doi.org/10.1101/2021.03.14.21253555 doi: medRxiv preprint It follows that

.

ConsequentlyẆ < 0 whenever Θ < 1. Furthermore,Ẇ = 0 implies that (1 − Θ) A ≤ 0. It follows that A = 0 and, thus, the fifth equation of system ((3.1)) becomes 

It follows that

, and lim

Therefore, applying the LaSalle-Lyapunov Invariance Principal, it follows that E is globally stable.

. CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted March 17, 2021. ; https://doi.org/10.1101/2021.03.14.21253555 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted March 17, 2021. ; https://doi.org/10.1101/2021.03.14.21253555 doi: medRxiv preprint

Immunological memory and protective immunity: understanding their relation

SARS-CoV-2 vaccines: status report

Challenges in creating herd immunity to SARS-CoV-2 infection by mass vaccination

COVID-19 coronavirus vaccine to prevent or stop an epidemic as the sole Intervention

Why do SARS-CoV vaccines not exist? The pharma scientific intelligence and business model must be revisited!

A mathematical model reveals the influence of population heterogeneity on herd immunity to SARS-CoV-2

The time course of the immune response to experimental coronavirus infection of man

Humoral immune responses and neutralizing antibodies againstSARS-CoV-2; implications in pathogenesis and protective immunity. Biochemical and Biophysical Research Communications

The SARS-CoV-2 vaccine pipeline: an overview

Fundamentals of Vaccine Immunology

As vaccines emerge, a global waiting game begins

Vaccines against coronavirus : the state of the art. Vaccines (Basel)

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection

The vaccine industry. Plotkin's Vaccines. 41-50

Seasonal coronavirus protective immunity is short-lasting

Will an imperfect vaccine curtail the COVID-19 pandemic in the

Coronavirus: update related to the current outbreak of COVID-19

Impact assessment of containment measure against COVID-19 spread in Morocco

What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2

Middle East respiratory syndrome coronavirus: risk factors and determinants of primary, household, and nosocomial transmission

Will an imperfect vaccine curtail the COVID-19 pandemic in the

Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients

Prioritising COVID-19 vaccination in changing social and epidemiological landscapes

Immunological considerations for COVID-19 vaccine strategies

Looking beyond COVID-19 vaccine phase 3 trials

Vaccine against Covid-19 disease -Present status of development

Vaccine epidemiology: A review

The gradual release exit strategy after lockdown against COVID-19, The Lancet Regional Health-Western Pacific

Sur le signe de la partie relle des racines d'uneéquation algbrique

Wood and the NSW COVID-19 Schools Study Team, Transmission of SARS-CoV-2 in Australian educational settings: a prospective cohort study

COVID-19 Vaccine Predictions: Using Mathematical Modelling and Expert Opinions to Estimate Timelines and Probabilities of Success of COVID-19 Vaccines

Center for Global Development

Middle East respiratory syndrome. The Lancet

Quantifying early COVID-19 outbreak transmission in South Africa and exploring vaccine efficacy scenarios

COVID-19 vaccine development pipeline gears up

Mathematical modeling of COVID-19 transmission dynamics with a case study of Wuhan

The socio-economic implications of the coronavirus pandemic (COVID-19): a review

Clinical outcomes of a COVID-19 Vaccine: implementation over efficacy

What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2

Severe acute respiratory syndrome

Functional SARS-CoV-2-specific immune memory persists after mild COVID-19

From Vaccines to Memory and Back

Active Immunization. Principles and Practice of Pediatric Infectious Diseases

The COVID-19 vaccine development landscape

The Ministry of Health of Morocco, The Official Coronavirus Portal of Morocco

The Ministry of Interior of Morocco

The current and future state of vaccines, antivirals and genes therapies against emerging coronavirus. Front Microbiol

Reproduction numbers and subthreshold endemic equilibria for compartmental models of disease transmission

Next-generation vaccine platforms for COVID-19

Modelling COVID-19

Robust neutralizing antibodies to SARS-CoV-2 infection persist for months

The genetic, origin, and diagnosis of SARS-CoV-2

Subunit vaccines against emerging pathogenic human coronaviruses. Front Microbiol

Modes of transmission of virus causing COVID-19: implications for ICP precaution recommendations

Sci Brief-Transmission modes-2020.1-eng.pdf

WHO, News briefing on

The access to COVID-19 tools (ACT) accelerator. 2020

The push for a COVID-19 vaccine

More than 150 countries engaged in COVID-19 vaccine global access facility

Coronavirus disease (COVID-19): Herd immunity, lockdowns and COVID-19

Zoonotic origins of human coronaviruses

Progress and prospects on vaccine development against SARS-CoV-2. Vaccines (Basel)